InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.325 0.005 (1.52%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$99 Application for quotation of securities - RCE 1 Jul 2026 11:10AM $0.385 $0.325 fallen by 15.58%
$99 Application for quotation of securities - RCE 1 Jul 2026 11:04AM $0.375 $0.325 fallen by 13.33%
$99 AUD $3.7M Income Tax Refund Received 1 Jul 2026 9:07AM $0.405 $0.325 fallen by 19.75%
$99 Proposed issue of securities - RCE 26 Jun 2026 6:00PM $0.400 $0.325 fallen by 18.75%
$99 RCE Investor Presentation 26 Jun 2026 10:35AM $0.375 $0.325 fallen by 13.33%
$99 Proposed issue of securities - RCE 26 Jun 2026 10:19AM $0.460 $0.325 fallen by 29.35%
$99 Placement & SPP to raise $8 million 26 Jun 2026 10:03AM $0.460 $0.325 fallen by 29.35%
$99 Trading Halt 24 Jun 2026 10:08AM $0.460 $0.325 fallen by 29.35%
$99 Pause in Trading 24 Jun 2026 9:54AM $0.460 $0.325 fallen by 29.35%
$99 HREC Approval Accelerates Global Phase 3 DFI Strategy 22 Jun 2026 10:03AM $0.485 $0.325 fallen by 32.99%
$99 Addendum to Recce Signs Middle East Licensing Term Sheet 27 May 2026 1:49PM $0.580 $0.325 fallen by 43.97%
$99 Recce Signs Middle East Licensing Term Sheet 27 May 2026 9:48AM $0.525 $0.325 fallen by 38.10%
$99 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 5:03PM $0.480 $0.325 fallen by 32.29%
$99 Positive Regulatory Inspection Outcome for Phase 3 Trial 21 Apr 2026 10:52AM $0.545 $0.325 fallen by 40.37%
$99 Notification of cessation of securities - RCE 15 Apr 2026 5:28PM $0.520 $0.325 fallen by 37.50%
$99 Brazil Patent Granted for RECCE Anti-Infectives 24 Mar 2026 11:52AM $0.490 $0.325 fallen by 33.67%
$99 RCE Investor Webinar Presentation Deck 19 Mar 2026 10:43AM $0.460 $0.325 fallen by 29.35%
$99 RCE Investor Webinar Presentation 17 Mar 2026 3:00PM $0.460 $0.325 fallen by 29.35%
$99 Appendix 4D and Interim Financial Report 27 Feb 2026 6:02PM $0.540 $0.325 fallen by 39.81%
$99 Change of Director's Interest Notices (x5) 24 Feb 2026 5:51PM $0.570 $0.325 fallen by 42.98%
$99 Notification of cessation of securities - RCE 24 Feb 2026 5:17PM $0.570 $0.325 fallen by 42.98%
$99 Recce Enters Second U.S. Department of Defense R&D Agreement 2 Feb 2026 8:58AM $0.560 $0.325 fallen by 41.96%
$99 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 1:01PM $0.600 $0.325 fallen by 45.83%
$99 AUD $5.3m R&D Rebate Received 14 Jan 2026 10:37AM $0.670 $0.325 fallen by 51.49%
$99 RCE Awarded Advanced Overseas Finding up to A$85m 16 Dec 2025 9:48AM $0.600 $0.325 fallen by 45.83%

26 - 50 of 730 results

Page 2 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.